Circio secures new funding through convertible bond conversion and issuance

Circio Holding ASA has completed a conversion of NOK 2,000,000 in convertible bonds held by Atlas Special Opportunities, LLC. This conversion resulted in the issuance of 3,333,333 new shares at NOK 0.60 per share, leading to a share capital increase of NOK 1,999,999.80. The company's total share capital will now be NOK 65,305,046.40, divided into 108,841,744 shares.

In addition to the conversion, Circio has exercised its Additional Financing Commitment with Atlas. This involves Atlas subscribing to and paying for one tranche of convertible bonds, totaling NOK 4,000,000. This new funding arrangement follows an extension of the financing commitment announced in August 2025, providing funding flexibility through the fourth quarter of 2025.

Circio continues to develop its circular RNA vector expression technology and its legacy immuno-oncology program, TG01, targeting RAS-mutated cancers.